OBJECTIVES To assess the cost-effectiveness of using brentuximab vedotin (BV) in treating relapsed or refractory  Hodgkin Lymphoma compared to standard chemotherapy and allogeneic stem cell transplant in the Swedish healthcare setting. Brentuximab vedotin is a novel antibody drug conjugate targeting CD-30 and is indicated for treating relapsed/refractory Hodgkin Lymphoma. METHODS  A Markov model with a lifetime horizon was constructed to compare BV to chemotherapy or allogeneic stemcell transplant (alloSCT). The analysis had a societal perspective and included lost productivity using a human capital approach. The model uses comparators relevant to Sweden and all epidemiological and cost parameters were based on Swedish sources. Both costs and effects were discounted at 3% according to Swedish guidelines. Clinical effectiveness for BV was based on pivotal clinical trial results and published data from the literature for the comparators relevant to the reimbursement authorities and to enable long term modelling. Outcomes were measured in QALYs. Uncertainty was addressed both through probabilistic sensitivity analysis and one-way analyses of central variables.  RESULTS Brentuximab vedotin dominated alloSCT (i.e a lower treatment cost and a better health outcome) and the ICER when compared to chemotherapy was SEK 419 000 (€47 000). One-way sensitivity analyses showed that the results were stable when central variables were varied. The probabilistic analysis also showed that brentuximab vedotin had a high probability of being the most cost-effective treatment at the accepted threshold values for all scenarios. CONCLUSIONS The ICERs calculated were all below commonly accepted willingness to pay for a QALY in Sweden for both comparator scenarios. Brentuximab vedotin is a cost effective treatment option for relapsed/refractory Hodgkin Lymphoma in the Swedish health care setting.